tiprankstipranks
Bright Minds Biosciences (DRUG)
NASDAQ:DRUG
US Market
DRUG
Bright Minds Biosciences
RESEARCH TOOLSreports

Bright Minds Biosciences (DRUG) Stock News & Sentiment

280 Followers
Buy Rating on BMB-101 Driven by Strong Phase 2 Epilepsy Data, Differentiated Safety, and Prader–Willi Upside Supporting DCF Valuation
Premium
Ratings
Buy Rating on BMB-101 Driven by Strong Phase 2 Epilepsy Data, Differentiated Safety, and Prader–Willi Upside Supporting DCF Valuation
17d ago
DRUG
Compelling Phase 2 Data and Prader–Willi Upside Support Buy Rating and Favorable Risk/Reward for DRUG
Premium
Ratings
Compelling Phase 2 Data and Prader–Willi Upside Support Buy Rating and Favorable Risk/Reward for DRUG
2M ago
DRUG
De-Risked Neurology Pipeline and Pivotal 2026 Catalysts Underpin Buy Rating on BMB-101 Franchise
Premium
Ratings
De-Risked Neurology Pipeline and Pivotal 2026 Catalysts Underpin Buy Rating on BMB-101 Franchise
2M ago
DRUG
Bright Minds Biosciences Files Q1 FY2026 Financials Showing Strong Cash, Higher R&D Loss
Premium
Company Announcements
Bright Minds Biosciences Files Q1 FY2026 Financials Showing Strong Cash, Higher R&D Loss
2M ago
6K
DRUG
Bright Minds Biosciences Raises US$175 Million in Share Offering to Advance CNS Drug Pipeline
Premium
Company Announcements
Bright Minds Biosciences Raises US$175 Million in Share Offering to Advance CNS Drug Pipeline
3M ago
6K
DRUG
Bright Minds Biosciences Launches $175 Million Share Offering to Fund Neurology Drug Pipeline
Premium
Company Announcements
Bright Minds Biosciences Launches $175 Million Share Offering to Fund Neurology Drug Pipeline
3M ago
6K
DRUG
Bright Minds Biosciences Prices Upsized US$175 Million Public Offering and Ends ATM Program
Premium
Company Announcements
Bright Minds Biosciences Prices Upsized US$175 Million Public Offering and Ends ATM Program
3M ago
6K
DRUG
More DRUG News >

DRUG News on the Web

Bright Minds initiated with a Buy at Jefferies
TipRanks News
Bullish
Buy Rating on BMB-101 Driven by Strong Phase 2 Epilepsy Data, Differentiated Safety, and Prader–Willi Upside Supporting DCF Valuation
TipRanks News
Bullish
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
TipRanks News
Bullish
Bright Minds Biosciences Inc at TD Cowen Healthcare Conference Transcript
GuruFocus News
Neutral
DRUG: HC Wainwright & Co. Raises Price Target to $145, Maintains Buy Rating | DRUG Stock News
GuruFocus News
Bullish
Bright Minds price target raised to $145 from $115 at H.C. Wainwright
TipRanks News
Bullish
Compelling Phase 2 Data and Prader–Willi Upside Support Buy Rating and Favorable Risk/Reward for DRUG
TipRanks News
Bullish
BTIG Maintains Buy Rating for Bright Minds Biosciences (DRUG) with $147 Target | DRUG Stock News
GuruFocus News
Bullish

News Score - Last 7 Days

Neutral
DRUG
Sector Average
Media Buzz
This Week1 articles
Weekly Average1 articles
News Sentiment
This Week100%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DRUG’s Media Buzz Sentiment?
1 articles about DRUG were published this week. In an average week, 1 articles are published.
    What is DRUG’s weekly average amount of articles?
    In an average week, 1 articles about DRUG are published.
      What is DRUG’s News Sentiment?
      100% of articles about DRUG were positive this week, compared to its sector average of 68%.
        Healthcare Stocks that are Trending in the News
        ALLOAllogene Therapeutics
        TXTMProText Mobility
        REPLReplimune Group
        IVVDInvivyd
        SLPSimulations Plus
        Showing the stocks with the most bullish news sentiment over the past week